Opthea (OPT) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Key product and clinical development updates

• Lead molecule sozinibercept targets VEGF-C/D, aiming for superior vision outcomes in retinal diseases, especially wet AMD, with robust Phase II-b data showing statistical superiority over standard of care when combined with anti-VEGF-A.

• Two pivotal global Phase III trials (COAST and SHORE) are fully enrolled, with top-line data expected in Q2 and mid-year, respectively; both use Eylea and Lucentis as comparators and exclude RAP lesions to maximize success probability.

• The company has fast-track FDA designation, plans to submit a BLA in the first half of 2026, and anticipates potential approval by the end of 2026.

• Phase II-b results showed a 5.7-letter gain in harder-to-treat lesions and a 4.4-letter gain in the broader wet AMD population, with significant improvements in vision and anatomical outcomes.

• Safety profile is consistent with existing anti-VEGF-A therapies, and the company is also pursuing a diabetic macular edema (DME) indication and co-formulation for simplified administration.

Market opportunity and competitive landscape

• Wet AMD market is valued at $15 billion globally, with wet AMD alone representing $10 billion annually; even a 1% share equates to $100 million in sales.

• The product is designed for combination use with any anti-VEGF-A, fitting seamlessly into current retina clinic workflows without disrupting established care models.

• No other clinical-stage competitors are pursuing superiority over standard of care or targeting the VEGF-C/D pathway; the pivotal program aims for a broad label to allow use with any anti-VEGF-A.

• U.S. market is highly concentrated, with 500 clinics making up half the volume and four private equity groups owning 25% of the market, making it accessible for a biotech launch.

• Payers prioritize visual outcomes over injection intervals, aligning with the primary endpoint of the pivotal trials.

Financials, partnerships, and corporate strategy

• Cash position at end of December was $130 million, sufficient to reach top-line data; additional $170 million in funding secured from Carlyle and Abingworth.

• The company is open to partnership discussions outside the U.S. due to the complexity of international markets, while preparing for a direct U.S. launch.

• Investor days are scheduled in New York and Australia to engage stakeholders and provide updates.